Condition: Small Cell Lung Cancer · Sponsor: AbbVie
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Yale University School of Medicine /ID# 278181 | New Haven, Connecticut, United States | Recruiting |
| Ocala Oncology Center /ID# 278269 | Ocala, Florida, United States | Recruiting |
| Moffitt Cancer Center /ID# 277573 | Tampa, Florida, United States | Recruiting |
| Fort Wayne Medical Oncology And Hematology /ID# 277336 | Fort Wayne, Indiana, United States | Recruiting |
| Baptist Health Lexington /ID# 277729 | Lexington, Kentucky, United States | Recruiting |
| Dana-Farber Cancer Institute /ID# 277732 | Boston, Massachusetts, United States | Recruiting |
| Missouri Cancer Associates /ID# 278299 | Columbia, Missouri, United States | Recruiting |
| University Hospitals Cleveland Medical Center /ID# 277556 | Cleveland, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center /ID# 277929 | Houston, Texas, United States | Recruiting |
| Virginia Cancer Specialists - Fairfax /ID# 278298 | Fairfax, Virginia, United States | Recruiting |
| Grand Hopital de Charleroi - Les Viviers /ID# 276897 | Charleroi, Hainaut, Belgium | Recruiting |
| Groupe Sante CHC - Clinique du MontLegia /ID# 276783 | Liège, Liege, Belgium | Recruiting |
+ 49 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07155174